Insight Pharma Affiliated Reports Collection Announces Asset Purchase Terms and Agreements Report

Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics Report
InsightPharmaReports com
InsightPharmaReports com
Spread the Word
Listed Under

Market Report
Big Pharma


Needham - Massachusetts - US


April 27, 2012 - PRLog -- NEEDHAM, MASS. – Cambridge Healthtech Institute’s Insight Pharma Affiliated Reports Collection announces the Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics Report, published by Current Partnering.

This report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.

The report focuses on four primary types of asset available for purchase:

      • Business assets - the most common asset exchanging hands. Business assets are in the form of a business unit or subsidiary of a parent company. Common assets include territorial businesses or non-core businesses such as an OTC or diagnostics business, separate from the core business operations

      • Product assets - in the form of marketed product, clinical phase development compound, or drug delivery-compound combination. These assets are commonly available as a result of a merger or change in direction of the selling company. The buyer acquires the asset for global or territorial exploitation. It is often the case that the acquiring company is normally a competitor to the seller, but in this situation the trade is of mutual benefit
      • Royalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product
      • Technology assets - where a buyer is acquiring a technology platform, research program, patent portfolio or other intellectual property asset. The acquisition is often due to the technology being surplus to a sellers interests, but may also be as a consequence of a sale of assets in advance of the seller entering liquidation

Key Benefits:

      • In-depth understanding of product and asset purchase deal trends since 2000
      • Analysis of the structure of product and asset purchase agreements with numerous real life case studies
      • Comprehensive access to over 600 actual product and asset purchase contracts entered into by the world’s biopharma companies
      • Detailed access to actual product and asset purchase contracts enter into by the leading fifty bigpharma companies
      • Insight into the payment and deal terms included in a product and asset purchase agreement, together with real world clause examples
      • Understand the key deal terms companies have agreed in previous deals
      • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

For more information and to purchase this Insight Pharma Report, visit:

About Insight Pharma Reports

Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute.

Insight Pharma Reports offers our Affiliated Reports Collection which provides a repository of additional scientific and business resources. For more information, visit
Source:Insight Pharma
Email:*** Email Verified
Tags:Market Report, Big Pharma, Biotech, Pharmaceutical, R D, Reports, Diagnostic
Industry:Biotech, Reports, Science
Location:Needham - Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Insight Pharm Reports PRs
Trending News
Top Daily News
Top Weekly News

Like PRLog?
Click to Share